Infection‐related mortality after HLA‐identical and haploidentical hematopoietic cell transplantation using reduced‐intensity conditioning in an outpatient setting
暂无分享,去创建一个
J. Ancer-Rodríguez | D. Gómez-Almaguer | J. Jaime-Pérez | Eugenia M. Ramos-Dávila | O. Cantú-Rodríguez | J. D. Meléndez-Flores | C. H. Gutiérrez-Aguirre | L. Marfil-Rivera
[1] C. Solano,et al. Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs , 2021, PloS one.
[2] S. Pergam,et al. Infection related mortality in adults and children undergoing allogeneic hematopoietic cell transplantation: An Australian registry report. , 2021, Transplantation and cellular therapy.
[3] J. Sierra,et al. Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide , 2021, Bone Marrow Transplantation.
[4] D. Gómez-Almaguer,et al. Outpatient Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide Is Safe and Feasible. , 2021, Transplantation and cellular therapy.
[5] E. Albert,et al. Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching , 2020, Bone Marrow Transplantation.
[6] A. van Belkum,et al. Innovative and rapid antimicrobial susceptibility testing systems , 2020, Nature Reviews Microbiology.
[7] L. Galli,et al. Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA-matching. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] A. Vekhoff,et al. Infectious complications after post‐transplantation cyclophosphamide and anti‐thymocyte globulin‐based haploidentical stem cell transplantation , 2019, British journal of haematology.
[9] S. Montoto,et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors , 2019, Bone Marrow Transplantation.
[10] C. Teng,et al. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia , 2019, Transplant infectious disease : an official journal of the Transplantation Society.
[11] M. Akhtari,et al. Increased risk of 100-day and 1-year infection-related mortality and complications in haploidentical stem cell transplantation , 2019, Journal of blood medicine.
[12] A. Nademanee,et al. Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes , 2018, Blood.
[13] Chutima Kunacheewa,et al. Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis , 2018, BMC Cancer.
[14] D. Gómez-Almaguer,et al. Assessing the efficacy of an ambulatory peripheral blood hematopoietic stem cell transplant program using reduced intensity conditioning in a low-middle-income country , 2018, Bone Marrow Transplantation.
[15] P. Rancoita,et al. A New Clinicobiological Scoring System for the Prediction of Infection-Related Mortality and Survival after Allogeneic Hematopoietic Stem Cell Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] T. Walsh,et al. Multidrug‐resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin‐resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients , 2017, Transplant infectious disease : an official journal of the Transplantation Society.
[17] P. Westervelt,et al. Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation , 2016, Transplant infectious disease : an official journal of the Transplantation Society.
[18] C. Carlo-Stella,et al. Infections after T‐replete haploidentical transplantation and high‐dose cyclophosphamide as graft‐versus‐host disease prophylaxis , 2015, Transplant infectious disease : an official journal of the Transplantation Society.
[19] Karl Frauendorfer,et al. One million haemopoietic stem-cell transplants: a retrospective observational study. , 2015, The Lancet. Haematology.
[20] C. Huff,et al. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] K. Ballen,et al. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] S. Lee,et al. Infectious complications following allogeneic stem cell transplantation: reduced‐intensity vs. myeloablative conditioning regimens , 2013, Transplant infectious disease : an official journal of the Transplantation Society.
[23] Lanping Xu,et al. The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[24] Michael Boeckh,et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.
[25] G. Sauvageau,et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[26] F. Dulley,et al. Evaluation of early hospital discharge after allogeneic bone marrow transplantation for chronic myeloid leukemia. , 2007, Sao Paulo medical journal = Revista paulista de medicina.
[27] S. Lee,et al. Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea , 2004, Bone Marrow Transplantation.
[28] M. Maris,et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[29] P. Moreau,et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] W. Leisenring,et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. , 1997, The Journal of infectious diseases.
[31] M. Solh,et al. Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk In , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.